Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Dec 19, 2023 1:23pm
160 Views
Post# 35792080

RE:Exciting Developments Unveiled: A Deep Dive into Spectral's

RE:Exciting Developments Unveiled: A Deep Dive into Spectral's You're certainly in the correct range of where the share price could go.  I am one of the shareholders that think a buyout by Baxter could happen once the 90 patient mark is reached as it would give Vantive the "sizzle" at the time they do their IPO on Nasdaq. 

Value offered is anybody's guess but I would think it would be Canadian $4 to $5 a share at a minimum.  Glad to see so many of the real shareholders on here now with everyone getting excited.  We've all waited patiently for many years.
<< Previous
Bullboard Posts
Next >>